Zobrazeno 1 - 10
of 385
pro vyhledávání: ''
Autor:
Shohei Burns, Maya Vella, Alan Paciorek, Li Zhang, Chloe E. Atreya, Mary Feng, Robin K. Kelley, Margaret A. Tempero, Katherine Van Loon, Andrew H. Ko
Publikováno v:
American Journal of Clinical Oncology. 45:22-27
There are no formal guidelines for the management of patients with primary gastrointestinal (GI) cancers who have lung-exclusive or lung-predominant metastases. We performed a retrospective analysis to evaluate host and tumor characteristics of this
Autor:
Albert C. Lockhart, Andrea Wang-Gillam, Michael J. Naughton, Joel Picus, Rama Suresh, Feng Gao, Gretel Terrero, Maria Q. Baggstrom, Lauren Trull, Cynthia Ma, Paula M. Fracasso, Benjamin R. Tan, Manik Amin, Stephanie Belanger
Publikováno v:
American Journal of Clinical Oncology. 44:443-448
Introduction The mammalian target of rapamycin (mTOR) is a downstream mediator in the phosphatidylinositol 3-kinase/Akt signaling pathway, and plays a central role in cell proliferation, growth, differentiation, migration, and survival. Temsirolimus
Autor:
Pei Wang, Emanuela Taioli, Rajwanth R. Veluswamy, Raja M. Flores, Francesca Petralia, Stephanie Tuminello
Publikováno v:
Am J Clin Oncol
Introduction The role of specific immune cell types within the tumor immune microenvironment in non-small cell lung cancer survival is unclear. The potential of these immune cells to become predictive biomarkers of prognosis, and to define subpopulat
Autor:
Jason Liu, Emily Bratton, Xinyan Yu, Colton Ladbury, Joseph Wagner, Howard West, Erminia Massarelli, Ravi Salgia, Ranjan Pathak, Victoria Villaflor, Miguel Villalona-Calero, Arya Amini
Publikováno v:
American journal of clinical oncology. 45(2)
The recommended treatment for patients with unresectable stage 3 non-small cell lung cancer (NSCLC) is definitive chemoradiation followed by 1 year of maintenance durvalumab. Our objective was to assess the rate of maintenance durvalumab use after ch
Autor:
Zuleyha Akgun, Serap Akyurek, Batuhan Bakirarar, Melek Tugce Yilmaz, Mustafa Cengiz, Sumerya Duru Birgi, Esra Sağlam, Pervin Hurmuz
Publikováno v:
American journal of clinical oncology. 45(1)
OBJECTIVE It is aimed to investigate the survival outcomes and prognostic factors after curative treatment of patients diagnosed with synchronous oligometastatic non-small cell lung carcinoma. MATERIALS AND METHODS Fifty-two patients from 3 centers d
Autor:
Kazuhisa Asai, Kazuto Hirata, Tatsuo Kimura, Yoshiya Matsumoto, Takashi Yana, Tomoya Kawaguchi, Kenji Sawa, Toshiyuki Nakai, Shigeki Mitsuoka, Naruo Yoshimura
Publikováno v:
American journal of clinical oncology. 44(12)
Objectives We conducted a clinical phase II study to evaluate the modified weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) regimen in pretreated patients with advanced non-small cell lung cancer (NSCLC). Materials and methods This multi
Publikováno v:
American Journal of Clinical Oncology. 43:741-747
OBJECTIVES Sociodemographic disparities in lung cancer prevalence, treatment options offered, and outcomes have been well documented. In stage I non-small cell lung cancer (NSCLC), the standard of care is surgical resection. This study explores dispa
Publikováno v:
American Journal of Clinical Oncology. 43:636-639
OBJECTIVES Cancer patients are using medical cannabis (MC) to address symptoms; however, little data exist to guide clinicians when counseling patients. We seek to define the patterns of MC use among cancer patients, as well as efficacy and safety of
Publikováno v:
American Journal of Clinical Oncology
Supplemental Digital Content is available in the text.
Objective: We aim to develop and validate an effective nomogram prognostic model for patients with typical lung carcinoid tumors using a large patient cohort from the Surveillance, Epidemiol
Objective: We aim to develop and validate an effective nomogram prognostic model for patients with typical lung carcinoid tumors using a large patient cohort from the Surveillance, Epidemiol
Publikováno v:
American Journal of Clinical Oncology. 43:582-585
OBJECTIVE Surgery for early stage non-small cell lung cancer can be curative. A delay from diagnosis to surgery can lead to increased mortality. Our objective was to determine if referring patients to specialists before a thoracic surgeon caused a de